Royalty Report: Drugs, Cancer, Pharmaceuticals – Collection: 28100

$100.00

Curated Royalty Rate Report
Created On: 2020-07-15, Record Count: 3

Description

This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Created On: 2020-07-15
Record Count: 3

Primary Industries

  • Drugs
  • Cancer
  • Pharmaceuticals

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 28100

License Grant
The Licensee entered into an exclusive License Agreement with an undisclosed foreign pharmaceuticals Licensor, giving the Licensee the right to sell a liquid medicine for the treatment of breast cancer in the United States of America. The License may be sub-Licensed; however, all terms remain the same.
License Property
In January 2012 the Licensee acquired a specialty pharmaceutical company, which holds an exclusive license for an oral liquid formulation for the treatment of breast cancer.

IPSCIO Record ID: 28789

License Grant
The Licensor entered into a License Agreement with the Licensee in relation to EVO 022, EVO 033 and EVO 044. EVO 022 is a combination drug therapy which is focused on the treatment of breast cancer. EVO 033 is a reformulation of an off patent novel anti microtubule agent targeted against breast cancer. EVO 044 utilises a stem cell technology to form bone marrow.
License Property
The Licensor acquires, develops and commercializes drugs to treat a variety of cancers, including pancreatic, renal and small-cell lung cancer.
Field of Use
The Licensee is a Pharmaceutical Company.

IPSCIO Record ID: 7779

License Grant
The Licensor grants the Licensee of the United Kingdom, during the Term, the exclusive right and license, with the right to subcontract and sublicense, under the Licensed Know-How and Licensed Patents, to undertake the Activities in respect of the Licensed Product in the Territory solely for use in the Field.
Licensor also grants the exclusive right and license, with the right to subcontract and sublicense, to use the Licensed Trademark, solely in connection with the Activities in respect of the Licensed Product in the Territory for use in the Field.
License Property
The Licensor has developed and received FDA approval of liquid tamoxifen known as “Soltamox®” for the treatment of breast cancer.
Field of Use
Field means cancer indication in humans.

The Licensee is interested in obtaining an exclusive license to market, promote and sell Soltamox product in the United States of America.

Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.